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Abstract
Background: Inflammation is known to play a pivotal role in mediating neuronal damage and axonal injury in a
variety of neurodegenerative disorders. Among the range of inflammatory mediators, nitric oxide and hydrogen
peroxide are potent neurotoxic agents. Recent evidence has suggested that oligodendrocyte peroxisomes may
play an important role in protecting neurons from inflammatory damage.
Methods: To assess the influence of peroxisomal activation on nitric oxide mediated neurotoxicity, we investigated
the effects of the peroxisomal proliferator activated receptor (PPAR) gamma agonist, pioglitazone in primary
cortical neurons that were either exposed to a nitric oxide donor or co-cultured with activated microglia.
Results: Pioglitazone protected neurons and axons against both nitric-oxide donor-induced and microglia-derived
nitric oxide-induced toxicity. Moreover, cortical neurons treated with this compound showed a significant increase
in the protein and gene expression of PPAR-gamma, which was associated with a concomitant increase in the
enzymatic activity of catalase. In addition, the protection of neurons and axons against hydrogen peroxide-induced
toxicity afforded by pioglitazone appeared to be dependent on catalase.
Conclusions: Collectively, these observations provide evidence that modulation of PPAR-gamma activity and
peroxisomal function by pioglitazone attenuates both NO and hydrogen peroxide-mediated neuronal and axonal
damage suggesting a new therapeutic approach to protect against neurodegenerative changes associated with
neuroinflammation.
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Background
Axon injury and neuronal loss are major pathological
substrates for permanent neurological disability in many
neurological diseases [1]. In several central nervous sys-
tem disorders activated inflammatory cells produce large
quantities of reactive oxygen species (ROS) and nitrogen
species (RNS) such as superoxide, hydrogen peroxide
and nitric oxide (NO) that can oxidize and damage pro-
teins, nucleic acids and lipids leading to mitochondrial
damage [2] with associated neuronal injury and axonal
degeneration [3]. In particular, microglia-derived NO
has been shown to be neurotoxic in vitro [4,5] and our
recent work has demonstrated that microglia-derived
NO significantly reduces the number of phosphorylated
neurofilaments within axons, leading to structural
instability and ultimately axonal degeneration [6,7].
The detoxification of ROS through the action of anti-
oxidant enzymes such as superoxide dismutase and cata-
lase, is a major intrinsic defense mechanism against
inflammatory tissue damage. Catalase is predominantly
located in peroxisomes where it catalyzes the conversion
of hydrogen peroxide into water and molecular oxygen
[3]. As well as performing an important role in the
detoxification of ROS, peroxisomes are also responsible
for the synthesis of plasmalogens and b-oxidation of
very long chain fatty acids (VLCFAs) [8]. Interestingly,
abnormalities in peroxisomal function have been linked
to a variety of neurological disorders including the
inflammatory demyelinating disorder, X-linked
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demonstrated that peroxisomes appear to be indispensi-
ble within oligodendrocytes for the maintenance of mye-
lin and for the integrity of axons [9,10] as
oligodendrocyte restricted elimination of peroxisomes is
associated with axonal damage, neuroinflammation and
subcortical demyelination [10]. Furthemore, an associa-
tion between neuroinflammation and impaired peroxiso-
mal function has also been demonstrated in a model of
experimental autoimmune encephalomyelitis [11].
Peroxisome proliferator-activated receptor-g (PPAR-g)
is a ligand-activated nuclear transcription factor [12]
that is predominantly expressed in adipose tissue, the
immune system [13] and also in primary rat microglial
[14] and neuronal cultures [15]. It is a target of the class
of drugs known as thiazolidinediones (TZDs), used to
treat type II diabetes and is known to regulate lipid and
carbohydrate metabolism [16-18] and act as a negative
regulator of macrophage and microglial activation
[14,19,20]. More recently, PPAR-g agonists have received
considerable attention as potential therapeutic agents for
a wide range of neurological diseases, including neuro-
degenerative diseases, traumatic injuries, stroke and
demyelinating diseases [21,22]. Indeed, several studies
have indicated that PPAR-g ciaos can prevent or attenu-
ate neurodegeneration [23-25] and have beneficial
effects in the amelioration of experimental autoimmune
encephalomyelitis (EAE)[ 2 6 - 3 1 ]w h i c hc o u l db e
explained in part because of anti-inflammatory action
exerted through PPAR-g activation in glial cells
[14,32-34]. PPAR-g can activate genes with a peroxisome
proliferator response element (PPRE) in their promoter
regions [35]. Indeed, the catalase promoter is known to
contain functional PPAR-g responsive elements, so it is
possible that the activity of catalase could be regulated
by PPAR-g agonists [36].
In our study, we evaluated the neuroprotective proper-
ties of the PPAR-g agonist pioglitazone on cortical neu-
rons exposed to inflammatory mediators, and assessed
whether pioglitazone influences axonal morphology and
peroxisomal function. Our experiments show that pio-
glitazone is capable of protecting cortical neurons from
the NO donor DETANONOate, hydrogen peroxide and
from microglia-derived injury. Pretreatment with piogli-
tazone was also observed to increase the total levels of
phosphorylated neurofilament within axons. Further-
more, we provide evidence that pioglitazone can induce
the expression of PPAR-g and the activity of catalase, a
key peroxisomal enzyme. These findings suggest that
activation of PPAR-g protects cortical neurons against
NO and hydrogen peroxide-dependent toxicity by a




The PPAR-g agonist, pioglitazone was purchased from
Cayman Chemical (Ann Arbor, Michigan, USA) and the
PPAR-g antagonist, GW9662, the catalase inhibitor, 3-
aminotriazole (3-AT) and catalase extracted from
human erythrocytes were obta i n e df r o mS i g m a - A l d r i c h
(Gillingham, UK). Pioglitazone and GW9662 were dis-
solved in dimethyl sulfoxide (DMSO) to reach the stock
concentration of 100 mM and serial dilutions were pre-
p a r e du s i n gD M S Oa n ds t o r e di na l i q u o t sa t−20°C.
Final working concentrations of 10 μM, 1 μMa n d0 . 1
μM were used in minimal media (DMSO, final concen-
tration 0.1%, V/V). A vehicle control with a final con-
centration of 0.1% DMSO (v/v) was used alongside each
experiment. 3-AT was dissolved in sterile distilled water
to reach the concentration of 1 M. Final working con-
centration of 10 mM 3-AT was used in minimal media.
Neuronal cell culture
Neuronal cultures were prepared from the cortices of
E18 rat embryos as previously described [37]. Following
enzymatic and mechanical dissociation, cells were
counted and plated onto poly-L-lysine coated 13 mm
coverslips at 250,000 cells/coverslip or onto poly-L-lysine
coated 96 well plates at 100,000 cells/well and cultured
in (D)MEM supplemented with 2% B27 (Gibco, Paisley,
UK) and 1% penicillin/streptomycin. After five days in
vitro (DIV), >95% of cells were positive for the neuronal
marker b-tubulin. At this point, cultures were exposed
to experimental conditions. The base medium for all
experiments was ‘minimal’, which consisted of (D)MEM
supplemented with insulin-free Sato (containing 100 μg/
ml BSA), 100 μg/ml transferrin, 0.06 μg/ml progester-
one, 16 μg/ml putrescine, 0.04 μg/ml selenite, 0.04 μg/
ml thyroxine, 0.04 μg/ml triiodothryonine).
Microglial cultures
Mixed glial cultures were prepared following the proto-
col of McCarthy and deVellis (1980), as described pre-
viously [37]. Briefly, forebrains of new-born (P2) rat
pups were removed and the meninges stripped before
mechanical and enzymatic dissociation. The resulting
cell suspension was plated onto poly-L-lysine coated 75
cm
2 tissue culture flasks. Culture medium ((D)MEM
plus 10% fetal calf serum) was changed at 24 hours and
twice weekly thereafter until the cells reached conflu-
ence after 10 to 12 days. At this stage, the loosely adher-
ent microglia on top of a confluent glial cell layer were
harvested by shaking at 700 rpm for 60 minutes. After
centrifugation (2,000 rpm for five minutes), cells were
re-suspended in serum-free (D)MEM supplemented
with 2% B27 (Gibco, Paisley, UK) and cultured in
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cells per well for 24 hours in (D)MEM supplemented
with 2% B27 (Gibco) and 1% penicillin/streptomycin
(B27 medium), prior to being exposed to experimental
conditions. The final supernatant from these shaken cul-
tures contained approximately 90% microglia as deter-
mined by immunocytochemistry using antibodies to
OX-42 (Abcam, Cambridge, UK)
Co-cultures of microglia and cortical neurones
Microglia within transwells were cultured in 2% B27
media for 24 hours. At this point, the transwells inserts
were added to cortical neuronal cultures (in 24-well
plates at 250,000 cells per well) already maintained for
five days in vitro and cultures were incubated in serum-
free defined medium for two days with or without Lipo-
polysaccharide (LPS)(1 μg/ml)/interferon (IFN) g (100
U/ml) and pioglitazone (1 μMo r1 0μM). DMSO was





- levels, measured with the Griess reagent, were
taken as an estimate of NO production. Griess reagent
(Sigma) was added to an equal volume of cell culture
supernatant (100 μl) and incubated for 20 minutesat
room temperature. The optical density was measured at
5 7 0n ma n das t a n d a r dc u r v ee s t a b l i s h e du s i n gN O 2
- at
a range of 1 to 100 μM.
Assays for cell survival
At five days in vitro culture, cortical neuronal cells were
exposed to experimental conditions. Media was removed
from all wells and cells were washed twice in (D)MEM.
(D)MEM/2% B27 medium (1 ml) or minimal media (1
ml) was added to appropriate wells. Pioglitazone, at the
concentrations described above was added one hour
before treatment with an NO donor. The nitric oxide
donor DETANONOate (0.1 mM) was applied to cul-
tures for 24 hours.
Evaluation of cortical neuronal cell survival was carried
out using 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assays, immunocytochemistry
and morphological examination of neuronal cultures
using the following methods.
MTT assay
The viability of cell cultures was estimated using MTT
(Sigma). This tetrazolium dye is oxidized by mitochon-
drial dehyrdrogenases and is a sensitive marker for
mitochondrial function. Cells were incubated with MTT
(1 mg/ml in PBS) for one hour at 37°C. Following this
incubation, the MTT solution was removed from the
plate and left to dry. DMSO (200 μl) was then added to
each well to dissolve the formazan crystals before the
optical density was measured at 540 nm.
Immunocytochemistry
Immunocytochemistry was used to identify cell pheno-
types and allowed examination of cellular morphology,
and PPARg expression. Neuronal cultures were stained
after fixation with 4% paraformaldehyde. Primary anti-
bodies against intracellular markers were used after
treatment of fixed cultures with 100% methanol for ten
minutes at −20°C. These were b-III tubulin (1:600)
(Sigma-Aldrich), SMI312 (phosphorylated neurofilament;
1:1000) (Covance, Cambridge, UK), and PPARg (1:200)
(Santa Cruz, Heidelberg, Germany). Species specific
(1:500) Alexa Fluor
® 488 and 555 conjugated secondary
antibodies (Invitrogen, Paisley, UK) were used to visua-
lize primary antibody staining. 4’,6-Diamidino-2-pheny-
lindole (DAPI) Vectashield™ {Vector Laboratories,
Peterborough, UK was used for nuclear identification.
Morphological analysis using immunocytochemistry
Neuronal cells were identified by b-III tubulin expres-
sion. In addition, nuclear staining (DAPI) of cells
enabled a morphological assessment of apoptosis. Neu-
ronal survival was assessed using counts of live b-III
tubulin positive stained cells as the ‘gold standard’.
These cultures exhibited a lack in apoptotic cell death
as evidenced by fewer condensed, fragmented nuclei. In
all cases, a control culture of cells grown throughout the
experimental period in (D)MEM/insulin-free Sato med-
ium referred to as ‘MIN’ was also analyzed and values
for experimental conditions were divided by this value
to standardize results between experiments.
Analysis of axons in culture
The antibody SMI312 (Covance) labels phosphorylated
neurofilaments and can be used to distinguish axons
from dendrites [38]. Cultures were stained for SMI312
after fixation and were viewed under a fluorescent
microscope with digital images (x40) taken of five ran-
dom fields within each culture (at least three culture
conditions per experiment). The images were analyzed
using Image J (NIH) and axon length was measured in
arbitrary units. Phosphorylated axons identified by
SMI312 immunoreactivity were traced using the free-
hand line tool. From the ‘set measurements’ function in
the tool bar, the length box was checked. Lengths of
processes staining positive for SMI312 per field were
obtained, together with the number of live cells per
field.
Western blotting
Neurons were cultured at high density (2 × 10
6 cells/
well) in a six well plate for five days before exposure to
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Beadlyte cell signalling universal lysis buffer (Millipore,
Watford, UK). The Quant-iT™ Protein kit (Invitrogen,
UK) was then used to quantify the concentration of
total protein within each cell lysate sample according to
manufacturer’s instructions to ensure equal loading of
cell lysates. Lysates were heated to 95°C for five minutes
with Laemmli 2 × sample buffer (Invitrogen) and run on
Tris-HCl 10 to 20% ready gels (Bio-Rad, Hemel Hemsp-
tead, UK,). After transfer to nitrocellulose membrane
(Bio-Rad) and blocking in 5% w/v BSA, membranes
were incubated overnight in primary antibody at 4°C (in
Tris-buffered saline/5% BSA). Antibodies used were
PPARg (1:5000) (Abcam) and GAPDH (1:15000)
(Abcam). Immunoreactivity was detected using second-
ary anti-rabbit and anti-mouse horseradish peroxidase
conjugated antibodies (Abcam) (in Tris-buffered saline/
5% BSA) and specific protein expression patterns were
visualized by chemiluminescence using a Geneflow Lim-
ited Western Blotting Detection System (Geneflow Lim-
ited, Staffordshire, UK). The optical density of the bands
(integrated density, arbitrary units) was measured by
Image J and levels of expression were calculated relative
to MIN control.
Catalase assay
Catalase activity was measured using the amplex
® red
catalase assay kit (Invitrogen). In the assay, catalase
activity is indirectly proportional to resorufin activity.
Neurons were cultured at high density (25 × 10
6 cells
per flask) in T175 flasks for five days before exposure to
test conditions. After 24 hours, cells were collected in
ice-cold PBS by scraping using a rubber policeman and
were pelleted by centrifugation at 2,000 g for 10 minutes
at 4°C. Following removal of the supernatant, the pellet
was homogenized in 50 mM phosphate buffer, pH 7
containing 1 mM ethylenediaminetetraacetic acid
(EDTA) and subsequently centrifuged at 10,000 g for 15
minutes at 4°C. Supernatants were stored in aliquots at
−80°C prior to being assayed for catalase activity follow-
ing the manufacturer’s instructions. The assay can
detect catalase in a purified system at levels as low as 50
mU/mL. All samples were analyzed in triplicate.
Real time PCR
Neurons were cultured at high density (2 × 10
6 cells/
well) in six well plates for five days before exposure to
test conditions. To investigate the effect of nitric oxide
and/or pioglitazone on gene expression, cells were trea-
ted with either vehicle or pioglitazone (1 μM) in combi-
nation with DETANONOate (0.1 mM) for one, two and
four hours. At each time point, RNA was extracted and
cDNA produced using the TaqMan gene expression
cells-Ct-kit (Applied Biosystems Paisley, UK) according
to the manufacturer’s instructions. A total of 10
5 cells
were added to the lysis solution plus DNase 1 (five min-
utes) before the addition of the stop solution (two min-
utes). The total RNA concentration was measured using
Quant-iT™ RNA kit (Invitrogen, UK). To synthesize
cDNA, the extracted RNA was placed in a thermal
cycler with the RT buffer and RT enzyme mix and incu-
bated at 37°C for one hour and 95°C for five minutes.
Real-time RT-PCR was performed using the Step One
Plus system (Applied Biosystems), with assay-on-
demand gene expression products for PPAR-g,n e u r o n -
specific enolase (Taqman MGB probes, FAM dye-
labeled, Applied Biosystems) and 18 S (VIC dye-labeled,
Applied Biosystems), gene Expression master mix and
2 . 5n go fc D N Ai nat o t a lv o l u m eo f2 0μl: 50°C for 2
minutes; 95°C for 10 minutes; and 40 cycles of 95°C for
15 minutes and 60°C for 1 minute. All samples were
analyzed in triplicate. Relative gene expression
(expressed as fold difference of each treatment relative
to the average of control treatment) was calculated
using the 2
-ΔΔCt method, and the average calculated for
each group. Separate calculations were made using 18 S
and neuron-specific enolase as the reference ‘housekeep-
ing’ gene.
Statistical analysis
Statistical comparisons were analyzed using one-way
analysis of variance ANOVA with post-hoc testing for
comparison of multiple sets (Bonferonni’s multiple com-
parison test). Paired t-tests were used for analysis of
data where values represented paired observations.
Values are expressed as the mean ± standard error of
the mean (SEM) from at least three independent experi-
ments, unless otherwise stated. Differences at P <0 . 0 5
were considered as statistically significant. Statistical
analyses were carried out with GraphPad Prism version
4.0 for Windows, GraphPad Software, San Diego, Cali-
fornia, USA.
Results
Pioglitazone exposure protects cortical neurons from NO-
mediated injury
To determine whether the PPAR-g agonist pioglitazone
could protect against the deleterious effects of a NO
donor, cortical neuronal cultures were incubated for 1
hour in the presence of increasing concentrations (10
nM to 100 μM) of pioglitazone prior to exposure to
DETANONOate (0.1 mM) for 24 hours. Cell viability
was evaluated by assessing the reduction of the tetrazo-
lium salt MTT, providing a general index of the meta-
bolic state. Neuronal viability was significantly reduced
when compared to control after nitric oxide exposure
( F i g u r e1 a ) .P r e l i m i n a r yd o s er e s p o n s ee x p e r i m e n t s
determined the range of concentrations which appeared
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concentrations (10 μM, 1 μMa n d0 . 1μM) of pioglita-
zone, neuronal viability was significantly increased dur-
ing exposure to nitric oxide (Figure 1a). To examine
whether the neuroprotection afforded by pioglitazone
was a receptor-dependent effect, neurons were exposed
to the specific PPAR-g antagonist GW9662 (1 μM) for 1
hour, prior to incubation with pioglitazone (1 μM). As
expected, neuronal viability was significantly increased
following exposure to pioglitazone and this effect was
abrogated in the presence of GW9662 (Figure 1b). Neu-
ronal viability was not significantly different following
exposure to the antagonist alone (Figure 1b). On the
basis of these results, the concentrations of pioglitazone
used to further study the effects of PPAR-g activation
on neuronal survival were determined. The final con-
centration of DMSO (vehicle) was always less than 0.1%
and had no effects on cell viability (data not shown).
Pioglitazone is neuroprotective and increases axonal
length in the presence of LPS and cytokine-stimulated
microglia
To determine the effect of pioglitazone on microglial
NO generation, the levels of nitrite production were
measured in microglia cultured alone or in transwell co-
cultures with cortical neurons (allowing for the
exchange of factors between microglia and neurons, but
no direct cell-cell contact). Two different doses of pio-
glitazone (1 μMa n d1 0μM) were administered to neu-
ronal-microglial transwell cultures and microglia
cultured alone, 1 hour before LPS (1 μg/ml) and IFN
(100 U/ml) treatment. LPS and IFN induced a signifi-
cant increase in NO generation after 48 hours (Figure
2a and 2b). However, pre-treatment with pioglitazone
failed to elicit a significant reduction in nitrite produc-
tion by microglia cultured alone (Figure 2a) or in trans-
well co-cultures (Figure 2b).
Induction of PPAR-g and catalase activity by pioglitazone
protects cortical neurons against inflammatory mediators
To further elucidate neuroprotective mechanisms of pio-
glitazone, we examined whether pioglitazone up-regu-
lates neuronal expression of PPAR-g at the transcript
and protein level. Under normal conditions, PPAR-g was
localized to the nucleus of cortical neurons and exhib-
ited a punctuate staining pattern (Figure 3a). Cortical
neurons were incubated with pioglitazone (1 μM) in the
presence or absence of DETANONOate (0.1 mM) for 1,
2a n d4h o u r s .I n c u b a t i o nw i t hp i o g l i t a z o n ei n d u c e da
significant increase in PPAR-g mRNA levels at 2 hours,
and also in neurons that were also exposed to DETA-
NONOate. Interestingly, exposure to DETANONOate
Figure 1 Effect of pioglitazone on DETANONOate-mediated
reductions in neuronal survival in cortical neuronal cultures.( a)
The effect of DETANONOate exposure (MIN NO) on cortical
neuronal cell viability in vitro compared to serum free minimal
media (MIN); and the effect of different concentrations (10 nM to 10
μM) of peroxisome proliferator activated receptor-g (PPAR-g) agonist,
pioglitazone (Pio) on cortical neuronal cell viability in vitro (***P <
0.001 compared to MIN and *P < 0.05 compared to MIN NO; n = 5).
Cultures were pre-treated with pioglitazone for 1 hour, prior to
exposure to DETANONOate. (b) The effect of pre-treatment with the
specific PPAR-g antagonist, GW9662 (1 μM) on cortical neuronal
viability in vitro compared to the effect of pioglitazone (1 μM) (***P
< 0.001 compared to MIN, *P < 0.05 compared to MIN NO and *P <
0.05 compared to MIN NO Pio 1 μM). Cultures were treated with
GW9662 for 1 hour prior to incubation with pioglitazone and
DETANONOate. Cell viability was assessed by MTT assay. Data are
expressed as percentage of cells grown in B27. Statistical
significance was obtained by one-way ANOVA followed by a
Bonferroni post-hoc test. ANOVA, analysis of variance.
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PPAR-g levels with no apparent additive effect of
DETANONOate and pioglitazone (Figure 3b). These
changes were independent of the 18 S neuron specific
enolase levels, used as endogenous controls. The effects
of pioglitazone on PPAR-g mRNA levels were paralleled
b yas i g n i f i c a n tr i s ei nP P A R - g protein levels over a 48-
hour period, as evaluated by western blot analysis (Fig-
ure 3c, d).
Enhancement of endogenous peroxisomal proliferation
by pioglitazone protects against hydrogen peroxide-
mediated neuronal injury
During inflammation, a major function of the peroxiso-
mal enzyme catalase is to convert hydrogen peroxide
(H2O2) into water. Therefore, having demonstrated
induction of catalase activityb yp i o g l i t a z o n ew ew i s h e d
to determine whether the pioglitazone could also protect
cortical neurons against H2O2-mediated injury. Neuro-
nal cultures were incubated for 1 hour in the presence
of increasing concentrations of pioglitazone (0.1 to 10
μM )p r i o rt oe x p o s u r et oh y d r o g e np e r o x i d e( 2 5 0μM).
Neuronal viability was significantly reduced when com-
pared to control after hydrogen peroxide exposure (250
μM for 24 hours; Figure 4a). In the presence of pioglita-
zone (10 μM, 1 μM and 0.1 μM), neuronal viability was
significantly increased during exposure to hydrogen per-
oxide (Figure 4a). Furthermore, the neuroprotective
effects of pioglitazone were prevented by the concomi-
tant presence of GW9662 (1 μM) suggesting that PPAR-
Figure 2 Effect of pioglitazone on microglial-induced neuronal and axonal loss in transwell co-culture. (a) Effect of pioglitazone (Pio; 1
and 10 μM) on nitrite production by microglial cultures either in the absence (MIN) or presence of LPS and IFN-g (MIN LPS IFN). Cultures were
exposed to IFN and LPS for 48 hours and nitrite levels measured in the culture supernatant (μM nitrite, **P < 0.01 compared to MIN; statistical
significance was obtained by one-way ANOVA followed by Bonferroni post-hoc test. (b) Effect of pioglitazone (Pio; 1 and 10 μM) on nitrite
production by neuron-microglia transwell co-cultures either in the absence (MIN) or presence of LPS and IFN-g (MIN LPS IFN). Cultures were
exposed to IFN and LPS for 48 hours and nitrite levels measured in the culture supernatant (μM nitrite, **P < 0.01 compared to MIN; statistical
significance was obtained by one-way ANOVA followed by Bonferroni post-hoc test). (c) Effect of pre-treatment with pioglitazone (1 and 10 μM)
on cortical neuronal survival in the presence of LPS and IFN-g activated microglia in transwell co-culture (number of b-III tubulin cells per field)
(**P < 0.01 compared to MIN LPS IFN, Student’s t-test). (d) Effect of pre-treatment with pioglitazone (1 and 10 μM) on total axon length (**P <
0.01 compared to MIN LPS IFN, Student’s t-test) in the presence of LPS and IFN-g activated microglia in transwell co-culture (length of SMI-312
axons per field). Photomicrographs showing immunoreactivity for b-III tubulin (red) and DAPI (blue) in neuron-microglia transwell co-cultures in
the presence of MIN LPS and IFN-g (MIN LPS IFN) (e) and (f) MIN LPS IFN-g and pioglitazone (10 μM) (MIN LPS IFN Pio 10 μM). ANOVA, analysis
of variance; DAPI, 4’,6-diamidino-2-phenylindole; IFN, interferon; LPS, Lipopolysaccharide. Microglial derived-nitric oxide has been shown to
mediate significant neuronal and axonal loss in vitro. We examined the influence of pioglitazone pre-treatment on neuronal survival and axonal
morphology in neuronal-microglial transwell co-cultures. Co-cultures were fixed and stained for bIII tubulin, SMI312 and the nuclear marker DAPI.
Pre-treatment with pioglitazone (10 μM) conferred a neuroprotective effect with a significant increase in neuronal (Figure 2c) and total axon
survival (Figure 2d) in transwell co-cultures of neurons and activated microglia. These data suggest that pioglitazone provides protection for
cortical neurons in neuron-microglia co-cultures through mechanisms which may be independent of its effects on nitrite reduction and that cell-
to-cell contact is not required for this to occur.
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neuroprotection of cortical neurons against the toxic
effects of hydrogen peroxide.
Discussion
In this study, we have performed a series of experi-
ments demonstrating that the PPAR-g agonist, pioglita-
zone is capable of promoting the survival of cortical
neurons in the presence of inflammatory mediators in
vitro, including microglia-induced injury in neuron-
microglia transwell cultures. In addition, we have
demonstrated that pioglitazone may have axonoprotec-
tive effects in vitro. Furthermore, this compound pro-
duced a two-fold increase in the specific activity of the
peroxisomal enzyme catalase, together with a signifi-
cant induction of PPAR-g gene expression, in the pre-
sence of a NO donor, suggesting that modulation of
PPAR-gamma activity and peroxisomal function by
pioglitazone may contribute to improved neuronal
survival.
Inflammation plays a pivotal role in the pathogenesis
of several neurological disorders [39]. Activated micro-
glia are capable of generating vast amounts of oxidizing
radicals such as superoxide, hydrogen peroxide and
nitric oxide [40] as well as proinflammatory mediators
such as proteases and arachidonic acid derivatives which
are all capable of eliciting tissue damage in the central
nervous system [41]. It has been previously
Figure 3 Effect of pioglitazone on PPAR-g expression and catalase activity in primary cortical neurons.( a) Photomicrograph showing
immunoreactivity for PPAR-g (red), bIII tubulin (green) and DAPI (blue). PPAR-g immunoreactivity shows a distinct punctuate nuclear staining
pattern. PPAR-g mRNA levels were measured by RT-PCR in (b) primary cortical neurons exposed to serum free minimal medium (MIN), minimal
medium plus DETANONOate (0.1 mM; MIN NO), pioglitazone (1 μM) (MIN PIO) or DETANONOate (0.1 mM) plus pioglitazone (1 μM; MIN NO PIO).
The fold difference relative to the average in control treated cells (MIN) was calculated for each treatment by the 2
-ΔΔCt method, with 18 S and
neuron-specific enolase as endogenous controls. Plots depict the levels of transcript for PPAR-g in cortical neurons following exposure to
experimental conditions for 1, 2 and 4 hours (*P < 0.05 compared to MIN for MIN NO, MIN PIO and MIN NO PIO at 2 hours, Student’s t-test). (c)
Immunoblotting of PPAR-g and loading control GAPDH in primary cortical neurons exposed to serum free minimal medium (MIN), minimal
medium plus DETANONOate (0.1 mM; MIN NO), pioglitazone (1 μM) (MIN PIO) or DETANONOate (0.1 mM) plus pioglitazone (1 μM; MIN NO PIO)
for 24 and 48 hours. (d) Western blot densitometric analysis of PPAR- g expression in cortical neurons derived from experimental conditions
outlined in (c) Data are given using arbitrary units of integrated density relative to MIN control (***P < 0.001, **P < 0.01 compared to MIN for
MIN PIO and MIN NO PIO respectively at 48 hours, Student’s t-test). (e) Effect of pioglitazone (Pio; 0.1 to 10 μM) on catalase enzymatic activity in
cortical neurons exposed to DETANONOate (0.1 mM for 24 hours; MIN NO) (*P < 0.05 compared to MIN and *P < 0.05, **P < 0.01, ***P < 0.001
compared to MIN NO, Student’s t-test). (f) Effect of pioglitazone (Pio; 0.1 to 10 μM) on catalase enzymatic activity in cortical neurons exposed to
serum free minimal medium (MIN) (*P < 0.05, compared to MIN, Student’s t-test). Data are expressed as mean ± SEM from at least three
separate experiments. DAPI, 4’,6-diamidino-2-phenylindole; PPAR-g, peroxisomal proliferator activated receptor g; SEM, standard error of the mean.
Furthermore, we examined whether pioglitazone up-regulated the activity of catalase, a specific peroxisomal enzyme, using a commercial assay
kit. Neurons treated with DETANONOate show a significant decrease in activity levels. However, pre-treatment with pioglitazone (10 μM, 1 μM
and 0.1 μM) in the presence of DETANONOate (0.1 mM) elicited a significant increase in catalase activity compared to treatment with
DETANONOate (0.1 mM) alone (Figure 3e). Furthermore, pioglitazone exposure alone (1 μM) elicited a significant increase in catalase levels
(Figure 3f).
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Page 7 of 12demonstrated that, at certain concentrations, the NO
donor, DETANONOate is directly neurotoxic [5,6] and
that microglial-derived NO significantly reduces the
number of SMI312-positive axons per surviving neuron
[6].
T h er o l eo fP P A R - g in regulating immune function
has been extensively investigated, with a previous study
demonstrating that pioglitazone can alleviate inflamma-
tion in experimental autoimmune encephalomyelitis
(EAE) and reduce clinical severity [27]. Furthermore,
Figure 4 Effect of pioglitazone on hydrogen peroxide-mediated reductions in neuronal survival in cortical neuronal culture.( a)T h e
effect of hydrogen peroxide exposure (MIN H2O2) (250 μM) on cortical neuronal viability in vitro compared to serum free minimal media (MIN)
(**P < 0.01 compared with MIN); the effect of pioglitazone (0.1 μMt o1 0μM; MIN H2O2 PIO) on cortical neuronal viability exposed to H2O2 (*P <
0.05 and **P < 0.01 as compared with MIN H2O2); and the effect of the PPAR-g antagonist, GW9662 (1 μM) on pioglitazone-induced
neuroprotection from H2O2 (**P < 0.01 comparing MIN H2O2 Pio 1 μM GW9662 1 μM with MIN H2O2 Pio 1 μM). Cultures were treated with
GW9662 for 1 hour prior to incubation with pioglitazone for 1 hour followed by exposure to hydrogen peroxide. Cell viability was assessed by
MTT assay. Data are expressed as percentage of cells grown in MIN medium. Statistical significance was obtained by one-way ANOVA followed
by Bonferroni post-hoc test. (b) Effect of hydrogen peroxide exposure (250 μM; MIN H2O2) on cortical neuronal cell survival (number of bIII-
tubulin cells per field; ***P < 0.001 as compared with MIN, Student’s t-test); the effect of pioglitazone (1 μM) on cortical neuronal survival
exposed to H2O2 (***P < 0.001 compared with MIN H2O2); and the effect of the PPAR-g antagonist, GW9662 (1 μM) on pioglitazone-induced
neuroprotection from H2O2 (**P < 0.01 comparing MIN H2O2 Pio 1 μM GW9662 1 μM with MIN H2O2 Pio 1 μM). (c) Effect of hydrogen peroxide
exposure (250 μMH 2O2) on axon length within neuronal cultures (determined by SMI312 staining; ***P < 0.001 as compared with MIN, Student’s
t-test); the effect of pioglitazone (1 μM) on axon length in neurons exposed to H2O2 (**P < 0.01 compared with MIN H2O2); and the effect of the
PPAR-g antagonist, GW9662 (1 μM) on pioglitazone-induced axon protection from H2O2 (***P < 0.001 comparing MIN H2O2 Pio 1 μM GW9662 1
μM with MIN H2O2 Pio 1 μM). Values represent the mean ± SEM from at least three separate experiments. ANOVA, analysis of variance; MTT, 3-
(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide; PPAR-g, peroxisomal proliferator activated receptor g; SEM, standard error of the mean.
To further examine the neuroprotective properties of pioglitazone, neurons were exposed to identical test conditions and cultures were then
fixed and stained for bIII tubulin, SMI312 and the nuclear marker DAPI. The numbers of viable neurons (determined by nuclear appearance)
expressing bIII tubulin were counted for each condition. As expected, neuronal survival was significantly increased following exposure to
pioglitazone (1 μM) (Figure 4b). In addition, we examined the influence of pioglitazone on axonal morphology in these cultures. Neurofilament
phosphorylation, as identified by the antibody SMI312, was examined as a marker of axonal integrity and length. Pre-treatment with pioglitazone
(1 μM) caused a significant increase in total axon survival (Figure 4c). Pre-treatment with GW9662 led to a significant reduction in the
neuroprotective (Figure 4b) and axonoprotective (Figure 4c) effects of pioglitazone. To determine further the role of catalase in pioglitazone-
induced neuroprotection, we pre-incubated the cultures with the catalase inhibitor 3-amino triazole (10 mM) (3-AT) for 1 hour, prior to
incubation with H2O2 (250 μM). The neuroprotective and axonoprotective effects of pioglitazone were attenuated by the addition of 3-AT (10
mM) (Figure 5a-5c). Furthermore, addition of exogenous catalase (100 U/ml) to cultures exposed to H2O2 improved neuronal survival (measured
by MTT assay (Figure 5a) and neuronal morphology (Figure 5b) and axonal length within cultures (Figure 5c).
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may reduce NO production by cultured microglial cells
in vitro [42-44]. In the current study, however, pioglita-
zone did not have any inhibitory effect on NO produc-
tion in IFN-g/LPS activated microglia cultured alone or
when neurons and microglia were separated with the
use of transwell co-cultures. Despite the failure of
pioglitazone to induce downregulation of NO produc-
tion under these experimental conditions, pioglitazone
(10 μM) significantly protected cortical neurons from
injury by IFN-g/LPS activated microglia in transwell co-
culture. The neuroprotective effect of pioglitazone in
transwell co-cultures cannot, therefore, be explained by
the reduction in microglial activation commonly
Figure 5 Inhibition of catalase activity attenuates pioglitazone-induced protection from H2O2 in cortical neuronal cultures.( a)T h e
effect of hydrogen peroxide exposure (MIN H2O2; 250 μM) on cortical neuronal viability in vitro compared to serum free minimal media (MIN)
(**P < 0.01 as compared with MIN); the effect of pioglitazone (1 μM) and the specific catalase inhibitor, 3-aminotriazole (3-AT) (10 mM) (**P <
0.01 MIN H2O2 compared to MIN H2O2 Pio 1 μM; and **P < 0.01 MIN H2O2 Pio 1 μM compared to MIN H2O2 Pio 1 μM 3-AT 10 mM) and the
effect of catalase exposure (MIN H2O2 CAT; 100 U/ml) (**P < 0.01 MIN H2O2 compared to MIN H2O2 CAT) on cortical neuronal viability. Cultures
were treated with pioglitazone for 1 hour prior to incubation with 3-AT for 1 hour followed by exposure to hydrogen peroxide. Cultures were
treated with catalase for 1 hour prior to exposure to hydrogen peroxide. Cell viability was assessed by MTT assay. Data are expressed as
percentage of cells grown in MIN medium. Statistical significance was obtained by one-way ANOVA followed by Bonferroni post-hoc test. (b)
Effect of hydrogen peroxide exposure (250 μMH 2O2) on cortical neuronal cell survival (number of bIII-tubulin cells per field; **P < 0.01 as
compared with MIN, Student’s t-test); the effect of pioglitazone (1 μM) on cortical neuronal viability exposed to H2O2 (*P < 0.05 compared with
MIN H2O2); the effect of catalase exposure (MIN H2O2 CAT; 100 U/ml) (**P < 0.01 MIN H2O2 compared to MIN H2O2 CAT) and the effect of the
specific catalase inhibitor, 3-AT (10 mM) on pioglitazone-induced neuroprotection from H2O2 (**P < 0.01 comparing MIN H2O2 Pio 1 μM with
MIN H2O2 Pio 1 μM 3-AT 10 mM). (c) Effect of hydrogen peroxide exposure (250 μMH 2O2) on axon length within neuronal cultures (determined
by SMI312 staining; **P < 0.01 as compared with MIN, Student’s t-test); the effect of pioglitazone (1 μM) on axon length in neurons exposed to
H2O2 (*P < 0.05 compared with MIN H2O2); the effect of catalase exposure (MIN H2O2 CAT; 100 U/ml) (**P < 0.01 MIN H2O2 compared to MIN
H2O2 CAT) and the effect of the specific catalase inhibitor, 3-AT, (10 mM) on pioglitazone-induced axon protection from H2O2 (**P < 0.01
comparing MIN H2O2 Pio 1 μM with MIN H2O2 Pio 1 μM 3-AT 10 mM). Values represent the mean ± SEM from at least three separate
experiments. ANOVA, analysis of variance; MTT, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide; SEM, standard error of the mean.
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Page 9 of 12observed when PPAR-g agonists are used [42-44], and
suggests that the major effects of pioglitazone may
occur through a primary protective effect specifically on
neurons. However, the possibility should be considered
that pioglitazone may exert an inhibitory effect on the
microglial secretion of inflammatory mediators which
may contribute to the observed neuroprotective effects
[43].
Activated microglia are capable of causing widespread
tissue damage in neuroinflammatory disorders [45,46]
through their generation of vast amounts of oxidizing
radicals, such as superoxide, hydrogen peroxide and
nitric oxide [40]. In addition to demonstrating a protec-
tive effect of pioglitazone on neurons, we examined
whether this drug could influence axonal morphology in
the presence of activated microglia. Neurofilament phos-
phorylation is vital in the maintenance of axon stability
and dephosphorylation of neurofilaments occurs within
axons of inflammatory disorders such as multiple sclero-
sis leading to subsequent axon degeneration [47]. Our
results demonstrate that microglial derived NO signifi-
cantly reduces the total number of SMI-312-positive
axons per field and that pioglitazone attenuates this
severe microglia derived NO-mediated axon destruction.
Interestingly, when NO is secreted, it can intereact
with O2
- to form peroxynitrite (ONOO
-), an anion with
strong oxidant properties [48]. Anti-oxidant enzymes
such as Cu/Zn superoxide dismutase (SOD), Mn SOD
and catalase (the latter being mainly localized to peroxi-
somes), work in concert to detoxify superoxide radicals
into water and oxygen [49].We found that activation of
PPAR-g with neuroprotective doses of pioglitazone upre-
gulated the expression of the PPAR-g receptor and the
activity of catalase, thus providing cortical neurons with
a higher anti-oxidant capability. These results are con-
sistent with the ability of PPAR-g agonists to upregulate
the levels of anti-oxidant enzymes in other experimental
paradigms [49-52]. Furthermore, it is known that cata-
lase contains functional PPAR-g response elements in its
promoter region [36], thus explaining the upregulation
of this enzyme by pioglitazone.
In addition, our study confirmed a previous report
[15] that cortical neurons express PPAR-g,w i t hi t s
immunoreactivity being clearly localized to the nucleus.
Neuroprotective doses of pioglitazone elicited a five-fold
increase in the transcription of PPAR-g, suggesting the
existence of a positive feedback mechanism by which
pioglitazone could sustain the responsiveness of cortical
neurons by increasing the expression of its receptor.
Interestingly, this early rise in PPAR-g gene transcription
was seen in neurons also exposed to the NO donor, sug-
gesting that the effect of PPAR-g agonism on PPAR-g
gene expression can occur independently of co-signal-
ling with inflammatory mediators.
Anti-oxidant enzymes such as catalase and glutathione
peroxidase work in concert to detoxify hydrogen perox-
ide into water and oxygen. We have demonstrated that
neuroprotective doses of pioglitazone elicited a signifi-
cant increase in activity of catalase. Therefore, in addi-
tion, we examined whether pioglitazone could also
protect cortical neurons against the neurotoxic effects of
hydrogen peroxide. As expected, pioglitazone (1 μM),
protected cortical neurons from injury by hydrogen per-
oxide. Furthermore, our results demonstrate for the first
time, that hydrogen peroxide reduces the total number
of SMI312-positive axons, and that pioglitazone attenu-
ates this severe H2O2-mediated axon destruction. Neu-
roprotection afforded by pioglitazone against both NO
and H2O2 was abrogated by the presence of the specific
PPAR-g antagonist, GW9662. This is in accordance with
a previous study whereby pioglitazone was found to
exert its effects via a receptor-dependent mechanism
[49].
Conclusions
Taken together, our results show that activation of
PPAR-g by pioglitazone protects against neuronal cell
death and axonal damage in in vitro models of inflam-
mation, and provides further evidence of the neuropro-
tective effect provided by enhancement of endogenous
peroxisomal activity. Further studies using in vivo mod-
els of neuroinflammation are justified to investigate the
novel role of the PPARs in the prevention of the neuro-
nal and axonal damage.
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